Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 9Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2

Interventions

pembrolizumab 20Gemcitabine 18Cisplatin 14Magnetic Resonance Spectroscopy 13enfortumab vedotin 12Specimen Handling 10Cystectomy 10Docetaxel 8Mitomycin 7Standard of Care 6Cystoscopy 6Transurethral Resection of Bladder 5Radiotherapy 5Carboplatin 5durvalumab 4Practice Guidelines as Topic 4Nivolumab 4Radiation 3Multiparametric Magnetic Resonance Imaging 3Mitozytrex 3Fluorouracil 3tislelizumab 2dehydroftorafur 2cemiplimab 2avelumab 2alvimopan 2Therapeutics 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Urinary Bladder Neoplasms × 5-aminolevulinic acid hexyl ester × Clear all
NCT02660645 2025-12-18

BLCCR

Photocure

Recruiting
4,400 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡